2015
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Weintraub D, Simuni T, Caspell‐Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine M, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA, Initiative T. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Movement Disorders 2015, 30: 919-927. PMID: 25737166, PMCID: PMC4855523, DOI: 10.1002/mds.26170.Peer-Reviewed Original ResearchConceptsParkinson's Progression Markers InitiativeNeuropsychiatric symptomsPD patientsHealthy controlsProgression Markers InitiativeParkinson's diseaseCognitive impairmentUntreated PD patientsDopamine replacement therapySignificant depressive symptomsGroup differencesSymptoms of depressionQuality of lifeMild cognitive impairmentUntreated patientsDisease courseReplacement therapyICD symptomsControl disordersDepressive symptomsGeneral populationPatientsMeeting criteriaMulti-site studyBiological predictors
2012
The course of cognitive functioning over six months in individuals at clinical high risk for psychosis
Barbato M, Colijn MA, Keefe RS, Perkins DO, Woods SW, Hawkins KA, Christensen BK, Addington J. The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry Research 2012, 206: 195-199. PMID: 23159196, PMCID: PMC3600156, DOI: 10.1016/j.psychres.2012.10.013.Peer-Reviewed Original ResearchConceptsClinical high riskCHR individualsComprehensive cognitive test batteryCognitive test batteryCognitive impairmentFuture longitudinal researchCognitive functioningCognitive performanceCognitive testsTest batteryLongitudinal researchCognitionPoor performanceLongitudinal changesPsychosisIndividualsParticipantsImpairmentBaseline participantsFunctioningPerformanceBatteriesResearchProdromeGlycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptoms
2010
Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis
Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, Keefe RS, Heinssen R, Cornblatt BA. Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis. JAMA Psychiatry 2010, 67: 578-588. PMID: 20530007, PMCID: PMC3332118, DOI: 10.1001/archgenpsychiatry.2010.66.Peer-Reviewed Original ResearchConceptsFamily historyCHR individualsNeuropsychological functioningCHR syndromeNorth American Prodrome Longitudinal StudyClinical high-risk individualsHigh-risk groupFirst-episode schizophreniaBaseline neuropsychological evaluationHigh-risk individualsSecond-degree relativesHigh-risk statusLongitudinal studyGlobal neuropsychological functioningWorse verbal memoryPrediction of psychosisCHR assessmentSyndrome criteriaProspective evaluationClinical criteriaModerate severityNeurocognitive composite scorePsychosis onsetNormal controlsSubsequent psychosis
2005
Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample
Hoffman RE, Gueorguieva R, Hawkins KA, Varanko M, Boutros NN, Wu YT, Carroll K, Krystal JH. Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample. Biological Psychiatry 2005, 58: 97-104. PMID: 15936729, DOI: 10.1016/j.biopsych.2005.03.041.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationAuditory hallucinationsSham stimulationMagnetic stimulationTemporoparietal repetitive transcranial magnetic stimulationClinical Global Impression ScaleGlobal Impression ScaleRight-handed patientsMotor thresholdImpression ScaleRTMS effectsNew patientsNeurocognitive impairmentHallucination frequencySchizoaffective disorderPatient samplesSignificant distressPatientsChange scoresHallucinationsPreliminary reportStimulationNeurobiological factorsIntervention
2004
Factorial structure of the Scale of Prodromal Symptoms
Hawkins KA, McGlashan TH, Quinlan D, Miller TJ, Perkins DO, Zipursky RB, Addington J, Woods SW. Factorial structure of the Scale of Prodromal Symptoms. Schizophrenia Research 2004, 68: 339-347. PMID: 15099615, DOI: 10.1016/s0920-9964(03)00053-7.Peer-Reviewed Original ResearchNeuropsychological status of subjects at high risk for a first episode of psychosis
Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophrenia Research 2004, 67: 115-122. PMID: 14984870, DOI: 10.1016/j.schres.2003.08.007.Peer-Reviewed Original ResearchConceptsFirst episodeFirst psychotic episodeLevel of impairmentSchizophrenia prodromePsychotic episodeHigh riskMulti-site studyProdromal interventionPopulation normsNeuropsychological examNeuropsychological StatusNeuropsychological functioningNormal intelligenceEpisodesSchizophrenia samplePsychosisSubjectsRiskStatusProdromeSchizophreniaImpairmentSeverity
2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample
Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample. Schizophrenia Research 2003, 61: 19-30. PMID: 12648732, DOI: 10.1016/s0920-9964(02)00440-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsBenzodiazepinesBipolar DisorderComorbidityDepressive Disorder, MajorDouble-Blind MethodFemaleHumansMaleMood DisordersOlanzapinePirenzepinePsychomotor DisordersPsychotic DisordersRisk FactorsSchizophreniaSchizophrenic PsychologySleep Wake DisordersSpeech DisordersConceptsFirst-episode schizophreniaEpisode schizophreniaTreatment-seeking patientsClinical trialsDouble-blind placebo-controlled clinical trialProdromal SyndromesDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsMild affective symptomsNew diagnostic criteriaSerious mental illnessClinical trial samplesUntreated first-episode schizophreniaSubstance use/abuseEffects of drugsPutative prodromal syndromeUse/abuseUnusual thought contentAdolescent maniaOngoing symptomatologyProdromal sampleStudy medicationBaseline characteristicsMost patientsThe PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design. Schizophrenia Research 2003, 61: 7-18. PMID: 12648731, DOI: 10.1016/s0920-9964(02)00439-5.Peer-Reviewed Original ResearchConceptsPsychosis onsetClinical trialsDouble-blind placebo-controlled clinical trialStudy rationaleDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsNew diagnostic criteriaClinical trial designPutative prodromal syndromeTreatment-seeking patientsOngoing symptomatologyNeuroleptic medicationHigh riskDiagnostic criteriaTrial designEarly courseProdromal SyndromesClinical phenomenologyStudy designClinical populationsPatientsOnsetIntervention researchTrialsTranscranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations
Hoffman RE, Hawkins KA, Gueorguieva R, Boutros NN, Rachid F, Carroll K, Krystal JH. Transcranial Magnetic Stimulation of Left Temporoparietal Cortex and Medication-Resistant Auditory Hallucinations. JAMA Psychiatry 2003, 60: 49-56. PMID: 12511172, DOI: 10.1001/archpsyc.60.1.49.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationMedication-resistant auditory hallucinationsTranscranial magnetic stimulationLeft temporoparietal cortexAuditory hallucinationsSham stimulationMagnetic stimulationTemporoparietal cortexOpen-label trialMotor thresholdAntipsychotic medicationSustained reductionBrain areasSchizoaffective disorderCortical activationPossible treatmentNeuropsychological impairmentNeuropsychological assessmentPatientsAdditional studiesCortexStimulationTrialsHallucinationsTreatment effects
2001
Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia.
Diaz E, Levine HB, Sullivan MC, Sernyak MJ, Hawkins KA, Cramer JA, Woods SW. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. Journal Of Psychiatry And Neuroscience 2001, 26: 325-9. PMID: 11590972, PMCID: PMC167186.Peer-Reviewed Original ResearchConceptsMedication Event Monitoring SystemEvent Monitoring SystemFirst monthMedication complianceSchizoaffective disorderCompliance rateTypical antipsychotic treatmentMean compliance ratePsychiatric inpatient hospitalHospital readmission dataElectronic monitoring devicesConsecutive patientsMedication regimensMonth 3Antipsychotic treatmentReadmission dataInpatient hospitalPatientsMEMS capsSchizophrenic disordersBottle openingHospitalSchizophreniaMonthsDisorders